Obesity, NAFLD and Hyperglycemia
Conditions
Interventions
Moringa Polyphenols Group :1 solid drink containing 2 g of moringa polyphenols in the morning and 1 solid drink in the evening for 3 months, during which a dietary healthy lifestyle intervention was c
Moringa Polyphenols Placebo Group:1 sachet of a placebo solid drink without moringa polyphenols and the rest of the same composition in the morning and evening for 3 months, during which a dietary hea
Pheomelanin Group:Administration of Pu-erh tea extract 2.7g/day (with >60% theaflavins) for 3 months of intervention
Theaflavin Placebo Group:Equivalent placebo (beta dextrin with caramel coloring) similar in appearance to teosinte taken daily for 3 months of intervention
Conjugated linoleic acid Group:160ml of fermented milk rich in conjugated linoleic acid per day
Conjugated linoleic acid placebo group:Drinking the same dose of zero-added fermented milk every day
Sponsors
Kunming Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: Moringa polyphenol intervention trial: (1) BMI = 28kg/m^2, (2) no other chronic diseases, (3) understand the research steps and be willing to participate in the study. Theabrownin intervention trial: (1) age between 40~70 years old, (2) hyperglycemia patients: fasting blood glucose higher than 6.1mmol/L or 2-hour postprandial blood glucose higher than 7.8mmol/L. Non-alcoholic fatty liver intervention trial: 1) both men and women, aged 18-65 years old, (2) no history of alcohol consumption in the past three months or alcohol equivalent to alcohol < 140g per week for men and 70g <per week for women, (3) mild to moderate non-alcoholic fatty liver disease, (4) willing to receive at least 12 weeks of dietary intervention and health behavior intervention with fermented milk rich in conjugated linoleic acid, (5) strictly follow the experimental procedures.
Exclusion criteria
Exclusion criteria: Moringa polyphenol intervention trial: (1) unwilling to accept informed consent, (2) have other chronic diseases other than obesity, and (3) have participated in other clinical studies within 30 days. Theabrownin intervention trial: (1) severe cardiovascular and cerebrovascular diseases, severe kidney diseases, malignant tumors, etc., (2) participation in other clinical studies within 30 days, (3) cases that may affect clinical evaluation in the opinion of the competent doctor, or cases that are not suitable for clinical research. Non-alcoholic fatty liver disease intervention trial: (1) unwilling to accept informed consent, (2) participated in other clinical studies within 30 days, and (3) could not strictly follow the experimental procedures.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| body composition;Metabolomics;microbial diversity;Hypoglycemia;Glycosylated hemoglobin;Fasting insulin;Abdominal ultrasound;Lipid Indicators; | — |
Secondary
| Measure | Time frame |
|---|---|
| Liver and kidney function;Inflammatory factor; | — |
Countries
China
Contacts
Public ContactWu Shaoxiong
Kunming Medical University
Outcome results
None listed